MasterControl

Quality management and manufacturing execution software

Salt Lake City, Utah, United States

About MasterControl

MasterControl provides software solutions focused on Quality Management Systems (QMS) and Manufacturing Execution Systems (MES) for companies in regulated industries like pharmaceuticals, medical devices, and nutraceuticals. Its software streamlines Good Manufacturing Practice (GxP) workflows, ensuring that products are produced consistently and meet quality standards. This allows clients to maintain high quality while navigating complex regulatory requirements. MasterControl differentiates itself by offering comprehensive support services, including implementation and training, which help clients optimize their processes and reduce costs. The goal of MasterControl is to enable its clients to bring their products to market more quickly and safely while ensuring compliance with industry regulations.

Salt Lake City, UtahHeadquarters
1993Year Founded
$145.9MTotal Funding
SERIES_ACompany Stage
Enterprise Software, HealthcareIndustries
501-1,000Employees

Benefits

Health Insurance
401(k) Company Match
Unlimited Paid Time Off
Flexible Work Hours
Wellness Program
Dental Insurance
Vision Insurance
Life Insurance

Risks

AI Document Summarizer may struggle with complex regulatory documents, risking compliance.
Resistance to digital logbooks could slow adoption among traditional clients.
New CMO may introduce strategies misaligned with current customer expectations.

Differentiation

MasterControl's QMS is trusted by FDA, CDC, and ORA for compliance.
The AI-powered Document Summarizer reduces manual work in regulatory document management.
MasterControl Logbooks offer a digital solution for efficient log management and compliance.

Upsides

Growing demand for AI in QMS enhances MasterControl's market potential.
Cloud-based solutions increase scalability and data accessibility for MasterControl clients.
Electronic logbooks meet rising demand for data integrity and compliance.

Funding

Total raised$145.91 M
Latest valuation$1.30 B
StageSERIES_A
SERIES A
11/30/2022
$150
$1.30 B